CVRx (CVRX) Q1 2026 earnings review
Growth Reaccelerates as Sales Overhaul Pays Off
CVRx delivered a decisive Q1 beat, generating $14.8M in revenue against guidance of $13.7M–$14.7M. This 20% YoY jump represents a reversing trend from the sluggish 4% growth seen in Q4 2025, proving the painful 2025 sales force restructuring is finally yielding productivity. Gross margins expanded to a record 87%, prompting management to raise full-year margin guidance. However, the path to profitability remains long; the company posted a $13.1M net loss and burned $12.3M in cash as it absorbs the launch costs of its massive BENEFIT-HF clinical trial.
🐂 Bull Case
U.S. revenue surged 22% YoY, indicating that the new cohort of territory managers hired during the volatile 2025 overhaul are maturing and driving deep adoption.
Gross margins hit 87%, up from 84% a year ago. The company’s ability to drive ASP and manufacturing efficiencies is translating into improved unit economics.
🐻 Bear Case
Despite YoY strength, revenue fell 8% sequentially from Q4. The insurance deductible cycle remains a stubborn macro headwind for elective procedures.
Operating and investing cash burn was $12.3M for the quarter. With $72.3M in the bank and a multi-year, $20M+ clinical trial kicking off, capital discipline is critical.
⚖️ Verdict: 🟢
Bullish. Management promised that the 2025 sales disruption was a necessary step for long-term growth, and Q1 data validates that claim. Expanding margins and a revenue beat provide a strong foundation for 2026.
Key Themes
U.S. Sales Force Reaching Maturation
The core thesis behind CVRx's 2025 turbulence is playing out. U.S. revenue grew 22% YoY to $13.7M, accelerating sharply from Q4's 4% growth. The company successfully expanded to 56 U.S. sales territories (up 3 in the quarter) and grew active implanting centers to 257. The focus on 'deep adoption' over merely opening new accounts is working.
Margins Hit Record Highs
Gross margin is accelerating, hitting 87% in Q1 compared to 84% a year ago. This $2.6M (+25%) YoY increase in gross profit outpaced the 20% revenue growth, demonstrating excellent operational leverage as manufacturing efficiencies take hold. Consequently, management raised their FY26 margin guidance.
Category I CPT Codes Go Live
The highly anticipated transition to Category I CPT codes for the Barostim therapy took effect on January 1, 2026. This removes the automatic 'experimental' denial from payers, forcing human clinical review and cementing a national average physician payment. This structural tailwind removes a massive historical barrier to adoption.
European Segment Stagnation
While the U.S. narrative is decidedly positive, the data contradicts this internationally. European revenue decelerated and reversed, falling 2% YoY to $1.1M. Total revenue units in Europe dropped from 59 to 56, and sales territories remained completely flat at five. Europe has become a dead weight on the income statement.
Macro Seasonality Caps Momentum
Despite the strong YoY print, total revenue contracted 8% sequentially ($16.0M down to $14.8M). As flagged in prior years, the Q1 insurance deductible reset creates a macroeconomic seasonal hurdle for elective procedures. Until Barostim is viewed as critically urgent rather than elective, Q1 will remain structurally weak.
BENEFIT-HF Costs Inflating R&D
R&D expenses accelerated 23% YoY to $3.1M. This is directly tied to the activation of the first site and patient enrollment for the BENEFIT-HF trial. Management previously guided that this trial will cost $20-$30M over 5-7 years. As clinical expenses mount, the company's $72.3M cash pile gives them roughly 1.5 to 2 years of runway at current burn rates.
Other KPIs
Stable. Up only 3% YoY despite revenue growing 20%. This tight cost control indicates the company is successfully extracting operating leverage from its transformed sales force rather than just spending blindly for top-line growth.
Improving. A slight reduction from the $13.8M net loss in 25Q1, resulting in an EPS of -$0.50 vs -$0.53. The path to breaking even relies entirely on pushing revenue well past the $25M quarterly SG&A+R&D baseline.
Guidance
Decelerating slightly YoY but accelerating sequentially. The midpoint of $15.6M implies roughly 14.8% YoY growth compared to Q2 2025 ($13.6M). It represents a healthy sequential step-up as the Q1 seasonal headwinds fade.
Stable. Management maintained this guidance range, which implies roughly 15% YoY growth at the midpoint. Achieving the high end requires the new sales reps to maintain consistent, compounding adoption rates in Tier 1 and Tier 2 hospitals.
Accelerating. Raised from prior guidance of 84% - 86%. This reflects confidence in sustained manufacturing efficiencies and stable ASPs for the Barostim device.
Stable. Maintained from prior guidance. The bulk of this will be driven by field sales compensation and the ramp-up in BENEFIT-HF clinical trial costs.
Key Questions
Category I CPT Code Impact
With the Category I CPT codes active since January 1, what specific changes are you seeing in prior authorization approval rates and time-to-approval compared to Q4?
European Strategy
European revenue declined 2% YoY, and territories remain flat at five. Are you reallocating capital away from Europe to fund U.S. expansion, or is there a plan to revive international growth?
Gross Margin Ceiling
Gross margins hit an impressive 87% this quarter. Is this the new structural baseline, and what volume level is required to push margins into the 90% territory?
BENEFIT-HF Cash Burn Timing
How much of the $20-$30M estimated net cost for the BENEFIT-HF trial will be absorbed in 2026, and how does that impact the timeline for needing additional capital?